As of January 2023, our "Journal of Controversies Obstetrics & Gynecology and Pediatrics" has been published under the Medihealth Academy to publish all articles, reviews and case reports on Pediatrics, especially in the field of Obstetrics and Gynecology. In order to facilitate the citation of the articles, to take our place in internationally respected indexes and to reach a wider readership, we will pay attention to the fact that our article language is only English in terms of acceptance. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

EndNote Style
Original Article
Comparison of clinical and biochemical parameters in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome
Aims: We aimed to compare the clinical and the biochemical features of the ovulatory versus anovulatory phenotypes of polycystic ovary syndrome (PCOS).
Methods: This is a retrospective controlled trial conducted among the women who applied to the İstanbul Liv Vadi Hospital between 2021 and 2023 August and diagnosed as PCOS. PCOS patients (n=290) were diagnosed according to the Rotterdam 2003consensus criteria. Women’s clinical and biochemical parameters such as age, height, weight, body mass index (BMI), waist, hip, waist/hip ratio (WHR), fasting blood sugar (FBS), insulin, homeostatic model-assessment-insulin resistance (HOMA-IR), antimullerian hormone (AMH), follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) total cholesterol,triglyceride, dehydroepiandrosterone (DHEAS), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) of participants were compared between ovulatory and anovulatory phenotypes.
Results: The findings of the study did not demonstrate a statistically significant correlation between ovulatory and anovulatory phenotypes in relation to various factors, including height, weight, BMI, waist circumference, hip circumference, WHR, insulin levels, HOMA-IR, AMH, FSH, E2, TSH, total cholesterol, testosterone, free testosterone, DHEAS, LDL and cholesterol (p-value>0.05). A statistically significant difference was observed between the groups in terms of age, FBS, BMI, LH, and HDL levels.
Conclusion: In conclusion, there is no significant difference in PCOS’s ovulatory and anovulatory phenotypes in essential parameters such as insulin resistance and BMI.

1. Ayar Madenli A, Öz İ, Gürbüz T. The relationship between antimullerian hormone level and endometrial polyp frequency in patientswith polycystic ovary syndrome. J Med Palliat Care. 2022;3(3):263-267.https://doi.org/10.47582/jompac.1148111
2. Gleicher N, Darmon S, Patrizio P, Barad DH. Reconsidering thepolycystic ovary syndrome (PCOS). Biomedicines. 2022;10(7):1505.doi:10.3390/biomedicines10071505
3. Gürbüz T, Gökmen O, Güngör ND. Polikistik over sendromu bulunankadınlarda glikoz potasyum oranının tanısal değerinin insülin ilekarşılaştırılması. Çukurova Med J. 2021;46(1):381-386.
4. Alanya Tosun Ş, Gürbüz T, Cebi A, Tosun A, Gokmen O, Usta M.Association of increased levels of omentin-1 and carotid intima-mediathickness with early signs of cardiovascular risk in patients withpolycystic ovary syndrome: a prospective case control study. J ObstetGynaecol Res. 2022;48(1):169-177. doi:10.1111/jog.15077
5. Melo AS, Vieira CS, Barbieri MA, et al. High prevalence of polycysticovary syndrome in women born small for gestational age. Hum Reprod.2010;25(8):2124-2131. doi:10.1093/humrep/deq162
6. Balen AH, Rutherford AJ. Managing anovulatory infertility andpolycystic ovary syndrome. BMJ. 2007;335(7621):663-666. doi:10.1136/bmj.39335.462303.80
7. Shayan A, Masoumi S, Shobeiri F, Ahmadinia H. Analysis of the factorsaffecting polycystic ovary syndrome. Iranian J Obstet Gynecol Infertil.2017;19(36):11-18.
8. Gürbüz T, Gökmen O, Ayar Madenli A, Dilbaz B. R-Spondin1 andtumor necrosis factor-alpha in infertile women with polycystic ovarysyndrome: relationships with insulin resistance and other parameters. JHealth Sci Med. 2023;6(2):449-455.
9. Urhan E, Elbuken G, Hacioglu A, Karaca Z, Unluhizarci K, KelestimurF. Ovarian functions and polycystic ovary syndrome in adult womenwith type 1 diabetes mellitus in a Turkish population. J EndocrinolInvest. 2023;46(3):609-616. doi:10.1007/s40618-022-01946-9
10. Rababa’h AM, Matani BR, Yehya A. An update of polycystic ovarysyndrome: causes and therapeutics options. Heliyon. 2022;8(10):e11010.doi:10.1016/j.heliyon.2022.e11010
11. Paoli A, Mancin L, Giacona MC, Bianco A, Caprio M. Effectsof a ketogenic diet in overweight women with polycystic ovarysyndrome. J Transl Med. 2020;18(1):104. doi:10.1186/s12967-020-02277-0
12. Kordi M, Motiei Z, Amirsasan R, Letafatkar K. The effect of aerobicexercise on biochemical parameters in women with polycystic ovarysyndrome. Res Rehabil Sci. 2009;5(2):63-72.
13. Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristicsof women with polycystic ovaries and oligo-amenorrhoea but normalandrogen levels: implications for the management of polycystic ovarysyndrome. Clin Endocrinol (Oxf). 2007;66(4):513-517. doi:10.1111/j.1365-2265.2007.02764.x
14. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypicvariation in hyperandrogenic women influences the findings ofabnormal metabolic and cardiovascular risk parameters. J ClinEndocrinol Metab. 2005;90(5):2545-2549. doi:10.1210/jc.2004-2279
15. Burgers JA, Fong SL, Louwers YV, et al. Oligoovulatory andanovulatory cycles in women with polycystic ovary syndrome (PCOS):what’s the difference? J Clin Endocrinol Metab. 2010;95(12):E485-E489.doi:10.1210/jc.2009-2717
16. Kang H. Sample size determination and power analysis using theG*Power software. J Educ Eval Health Prof. 2021;18:17. doi:10.3352/jeehp.2021.18.17
17. Panidis D, Tziomalos K, Misichronis G, et al. Insulin resistance andendocrine characteristics of the different phenotypes of polycysticovary syndrome: a prospective study. Hum Reprod. 2012;27(2):541-549.doi:10.1093/humrep/der418
18. Hosseinpanah F, Barzin M, Keihani S, Ramezani Tehrani F, AziziF. Metabolic aspects of different phenotypes of polycystic ovarysyndrome: Iranian PCOS Prevalence Study. Clin Endocrinol (Oxf).2014;81(1):93-99. doi:10.1111/cen.12406
19. Gupta M, Yadav R, Mahey R, et al. Correlation of body mass index(BMI), anti-mullerian hormone (AMH), and insulin resistance amongdifferent polycystic ovary syndrome (PCOS) phenotypes - a cross-sectional study. Gynecol Endocrinol. 2019;35(11):970-973. doi:10.1080/09513590.2019.1613640
20. Al-Jefout M, Alnawaiseh N, Al-Qtaitat A. Insulin resistance and obesityamong infertile women with different polycystic ovary syndromephenotypes. Sci Rep. 2017;7(1):5339. doi:10.1038/s41598-017-05717-y
21. Shirazi FKH, Khodamoradi Z, Jeddi M. Insulin resistance and highmolecular weight adiponectin in obese and non-obese patientswith polycystic ovarian syndrome (PCOS). BMC Endocr Disord.2021;21(1):45. doi:10.1186/s12902-021-00710-z
22. Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S. Comparisonof the different PCOS phenotypes based on clinical metabolic, andhormonal profile, and their response to clomiphene. Indian J EndocrinolMetab. 2019;23(3):326-331. doi:10.4103/ijem.IJEM_30_19
23. Moghetti P, Tosi F, Bonin C, et al. Divergences in insulin resistancebetween the different phenotypes of the polycystic ovary syndrome. JClin Endocrinol Metab. 2013;98(4):E628-E637. doi:10.1210/jc.2012-3908
24. Mansour A, Mirahmad M, Mohajeri-Tehrani MR, et al. Risk factors forinsulin resistance related to polycystic ovarian syndrome in Iranianpopulation. Sci Rep. 2023;13(1):10269. doi:10.1038/s41598-023-37513-2
25. Guastella E, Longo RA, Carmina E. Clinical and endocrinecharacteristics of the main polycystic ovary syndrome phenotypes.Fertil Steril. 2010;94(6):2197-2201. doi:10.1016/j.fertnstert.2010.02.014
Volume 1, Issue 4, 2023
Page : 90-94